Clinical Trial: A Lot-to-Lot Consistency Clinical Trial of PCV13

U.S., Sept. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07832500) titled 'A Lot-to-Lot Consistency Clinical Trial of PCV13' on Sept. 16.

Brief Summary: A Phase IIIb clinical trial of 13-valent pneumococcal conjugate vaccine (PCV13)developed by Sinovac Life Science Co., Ltd will be conducted in children aged 2 to 5 years.

The objective of the study is to evaluate the the Lot-to-Lot consistency, immunogenicity and safety of Sinovac PCV13. The trial is a randomized, double-blind phase IIIb clinical trial.

Study Start Date: Sept., 2026

Study Type: INTERVENTIONAL

Condition: Pneumococcal Infectious Diseases

Intervention: BIOLOGICAL: Sinovac PCV13 lot 1

One dose of Sinovac PCV13 lot 1 (0.5ml) was admini...